The Commerce Department unveiled a $2B CHIPS‑funded quantum package that includes $1B for IBM’s new foundry and minority equity stakes in several startups.

Eli Lilly says its experimental drug retatrutide produced near‑surgical levels of weight loss in late‑stage trials, but analysts note higher side effects and access questions.

A new Frontiers study finds a small uptick in lung cancer incidence after COVID‑19, especially among current and former smokers, and points to the enzyme TYMP as a likely mechanism.

MIT leaders say federal research cuts and falling grad enrollment forced tighter budgets and fewer admissions — a shift President Sally Kornbluth calls "a striking loss."

A Lancet‑published consensus has renamed PCOS to PMOS to emphasize hormonal and metabolic causes. Patient groups are split as the three‑year roll‑out begins.

Ukrainian surgeons told Fort Bragg medics that drone swarms are stretching evacuations from minutes to days, forcing new training and underground care plans.

An LLM‑backed analysis finds D.C. and Maryland among the most exposed to AI‑driven task changes, and regional training programs are racing to respond.

Moderna, Praxis and other Massachusetts firms joined a new national alliance pushing a Vision 2030 plan to keep U.S. biotech competitive with China.

A Madison nonprofit won a federal voucher to speed FDA review of psilocybin for major depression, joining two other programs selected under an April executive order. Local researchers say the award validates years of work but leaves rollout questions.

Federal reporting says the FDA blocked publication of several studies that found rare serious side effects from COVID and shingles vaccines, prompting fresh questions about transparency.

Former NASA administrator Jim Bridenstine will run Rockville-based Quantum Space as CEO, joining a startup building refuelable, maneuverable Ranger spacecraft aimed at defense missions. The company says Ranger Prime is now targeting a 2027 launch window.

A West Health–Gallup poll finds many Americans consult AI for health questions — and roughly 14 million say AI advice led them to skip care. Stanford’s chief data scientist weighs in.

DOJ's rescheduling of medical cannabis is opening investor pipelines for cannabis drug startups, prompting private raises and IPO talk while banks and state rules still complicate the picture.